Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2018

At a glance

  • Drugs Carotuximab (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 26 Dec 2018 According to a TRACON Pharmaceuticals media release, details of the dose escalation portion of the study will be presented at the International Association for the Study of Lung Cancer (IASLC) annual meeting (Feb 2019).
    • 26 Dec 2018 According to a TRACON Pharmaceuticals media release, recruitment is ongoing in the two parallel expansion cohorts of the study. In each cohort 12 patients are planned to enroll. The company expects to present data for these expansion cohorts in mid-2019.
    • 26 Dec 2018 Results presented in a TRACON Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top